Link Between Arthritis Drugs and Alzheimer Disease Risk
Researchers sought to evaluate whether there is any evidence from real-world data on treatment with tofacitinib, tocilizumab, or tumor necrosis factor and the risk for ADRD.
Alzheimer Disease
Novel Plasma Biomarkers May Improve Prediction of Alzheimer Disease
Researchers established the Florida Consortium for African American Alzheimer’s Disease Studies to identify genetic risk factors and novel plasma biomarkers for AD.
Mortality Rates Rose During COVID-19 Among Medicare Beneficiaries With Dementia
In a cross-sectional study, researchers compared COVID-19 infection and mortality rates from 2019 and 2020 among Medicare enrollees with Alzheimer disease and related dementias.
Reductions in Amyloid Beta Plaques, P-Tau Seen With Aducanumab Over 2 Years Later
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Donepezil Transdermal Patch Approved for Alzheimer Disease
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.
A Drug Repurposing Analysis Identifies Sildenafil as an Alzheimer Disease Treatment
In this drug repurposing network analysis and retrospective case-control study, an Alzheimer disease (AD) endophenotype model was made using data from large-scale amyloid or tauopathy genome-wide association studies. Drugs approved by the United States Food and Drug Administration were evaluated for their effect on the AD endophenotype.
FDA Clears Language Independent Computerized Test to Detect Cognitive Impairment
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
FDA Assigns PDUFA Date for Donepezil Transdermal System
Adlarity is a once-weekly transdermal formulation of donepezil.
Gantenerumab Designated Breakthrough Therapy for Alzheimer Disease
The FDA has granted Breakthrough Therapy designation to gantenerumab, an anti-amyloid beta antibody, for the treatment of Alzheimer disease.
Eisai Begins Rolling BLA Submission of Lecanemab for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
- Loading...
Loading...
Next post in News
Loading... 
Loading...